Drug interactions and effects of combination therapy for pulmonary arterial hypertensio

Not Applicable

Recruiting

• Conditions: pulmonary arterial hypertension

• Registration Number: JPRN-UMIN000005464
• Lead Sponsor: Hamamatsu University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-19
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Unstable disease conditions. Disabilities of walk. Home oxygen therapy. Ineligible patients judged by principal. investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics in the last week of each phase: sildenafil, bosentan, ambrisentan and tadalafil. Exercise tolerability test: 6 minute walk test, shattle walking test and maximal oxygen consumption test.